EF Hutton analyst Michael Albanese assumed coverage of Upexi with a Buy rating and $7 price target. Upexi, formerly Grove, has shifted focus from a single product to be a wider product distribution and brand enterprise while evolving into an online reselling business, Albanese tells investors. He sees building momentum with its VitaMedica, Interactive, Cygnet and LuckyTail assets and thinks management has shown an ability to acquire, integrate and scale "accretive acquisitions" to add to its brands, Albanese added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on UPXI:
- Upexi reports record revenue of $17M through November 30th
- Upexi’s toy brand Tytan Tiles to launch in Walmart retail stores in January
- Upexi Revenue Increases 199% Year-Over-Year to $11.6 Million for Fiscal 2023 First Quarter
- Upexi Closes Acquisition of E-Core and its Subsidiaries, Adding Over $40 Million in Trailing Twelve Month Sales and Increasing Projected Calendar 2023 Sales to $100M
- Upexi Announces Sale of Select CBD Assets for $23.5 Million